FPA150 in Patients With Advanced Solid Tumors

EARLY_PHASE1TerminatedINTERVENTIONAL
Enrollment

95

Participants

Timeline

Start Date

March 27, 2018

Primary Completion Date

April 21, 2021

Study Completion Date

April 21, 2021

Conditions
Breast CancerOvarian CancerEndometrial CancerAdvanced Solid Tumors
Interventions
BIOLOGICAL

FPA150

A monoclonal antibody against B7-H4

BIOLOGICAL

Pembrolizumab

An anti-PD1 antibody

Trial Locations (18)

10408

National Cancer Center, Gyeonggi-do

13620

Seoul National University Bundang Hospital, Gyeonggi-do

37203

Sarah Cannon Research Institute, Nashville

48201

Karmanos Cancer Institute, Detroit

60077

Orchard Healthcare Research Inc., Skokie

73104

Stephenson Cancer Center, Oklahoma City

77030

The University of Texas MD Anderson Cancer Center, Houston

78229

South Texas Accelerated Research Therapeutics, San Antonio

84106

Utah Cancer Specialists, Salt Lake City

85258

Honor Health, Scottsdale

90048

Cedars-Sinai Medical Center, Los Angeles

90095

UCLA, Los Angeles

90403

Sarcoma Oncology Research Center, Santa Monica

99208

Medical Oncology Associates, PS, Spokane

06520

Yale Cancer Center, New Haven

03722

Severance Hospital, Seoul

05505

ASAN Medical Center, Seoul

06351

Samsung Medical Center, Seoul

Sponsors
All Listed Sponsors
lead

Five Prime Therapeutics, Inc.

INDUSTRY

NCT03514121 - FPA150 in Patients With Advanced Solid Tumors | Biotech Hunter | Biotech Hunter